Yong Hu

Dr. Yong Hu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2023 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
ZGZiheng Gong
Ziheng Gong
YWYanjie Wang
Yanjie Wang
LLLan Li
Lan Li
XLXuyang Li
Xuyang Li
Bo QiuBo Qiu
Bo Qiu
YHYong Hu
Yong Hu

9 June 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
ZLZilin Liu
Zilin Liu
XWXuezhong Wang
Xuezhong Wang
JLJianping Li
Jianping Li
XYXiaoming Yang
Xiaoming Yang
JHJun Huang
Jun Huang
YHYong Hu
Yong Hu

29 September 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HXHengte Xing
Hengte Xing
CLChuancai Liang
Chuancai Liang
CWChenyu Wang
Chenyu Wang
XXXiongfeng Xu
Xiongfeng Xu
YHYong Hu
Yong Hu
BQBo Qiu
Bo Qiu

28 August 2025 in Carbohydrate Polymers
Verified
Journal Article
Closed access
SYShiyuan Yao
Shiyuan Yao
TCTiantian Chen
Tiantian Chen
ZLZilin Liu
Zilin Liu
LFLihong Fan
Lihong Fan
YXYiju Xie
Yiju Xie
Yingying ChuYingying Chu
Yingying Chu

21 September 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
ZLZilin Liu
Zilin Liu
JHJun Huang
Jun Huang
XWXuezhong Wang
Xuezhong Wang
SDShuang Deng
Shuang Deng
JZJianlin Zhou
Jianlin Zhou
YHYong Hu
Yong Hu

14 September 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
DYDashuai Yang
Dashuai Yang
MZMingqiang Zhu
Mingqiang Zhu
XXXiangyun Xiong
Xiangyun Xiong
YSYang Su
Yang Su
FZFangrui Zhao
Fangrui Zhao
YDYouming Ding
Youming Ding
Background: The goal is to establish and validate an innovative prognostic risk stratification and nomogram in patients of hepatocellular carcinoma (HCC) with microvascular invasion (MVI) for predicting the cancer-specific survival (CSS).Methods: 1487 qualified patients were selected from the Surveillance, Epidemiology and End Results (SEER) database and randomly assigned to the training cohort and validation cohort in a ratio of 7:3. Concordance index (C-index), area under curve (AUC) and calibration plots were adopted to evaluate the discrimination and calibration of the nomogram. Decision curve analysis (DCA) was used to quantify the net benefit of the nomogram at different threshold probabilities and compare it to the American Joint Committee on Cancer (AJCC) tumor staging system. C-index, net reclassification index (NRI) and integrated discrimination improvement (IDI) were applied to evaluate the improvement of the new model over the AJCC tumor staging system. The new risk stratifications based on the nomogram and the AJCC tumor staging system were compared.Results: Eight prognostic factors were used to construct the nomogram for HCC patients with MVI. The C-index for the training and validation cohorts was 0.785 and 0.776 respectively. The AUC values were higher than 0.7 both in the training cohort and validation cohort. The calibration plots showed good consistency between the actual observation and the nomogram prediction. The IDI values of 1-, 3-, 5-year CSS in the training cohort were 0.17, 0.16, 0.15, and in the validation cohort were 0.17, 0.17, 0.17 (P<0.05). The NRI values of the training cohort were 0.75 at 1-year, 0.68 at 3-year and 0.67 at 5-year. The DCA curves indicated that the new model more accurately predicted 1-year, 3-year, and 5-year CSS in both training and validation cohort, because it added more net benefit than the AJCC staging system. Furthermore, the risk stratification system showed the CSS in different groups had a good regional division.Conclusions: A comprehensive risk stratification system and nomogram were established to forecast CSS for patients of HCC with MVI.